Zydus Cadila gets USFDA nod for multiple sclerosis treatment drug
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera) in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing.
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Dimethyl Fumarate Delayed-Release Capsules
Cadila: a formidable play in Covid times and beyond
Cadila is not only a credible Indian pharma striving for a Covid solution, but on a longer time scale is an interesting watch in the large-cap space witnessing a significant transformation in product portfolio. Zydus Cadila gets tentative USFDA approval to market anti-cancer drug
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives tentative approval from USFDA for Palbociclib Capsules CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Credit Rating
We would like to inform that CRISIL has, after due deliberations, reaffirmed its 'CRISIL A1+' (pronounced as CRISIL A one plus rating) on the Rs. 1,300 crore Commercial Paper (enhanced from Rs. 250 crore) of the Company. The credit rating letter dated September 21, 2020 received from CRISIL is enclosed. Need to invest Rs 5,000 crore to give all Indians COVID-19 vaccine, says Zydus Cadila Chairman
A vaccine is definitely needed to control the spread of this disease, but the vaccine alone is not enough, and other efforts such as social distancing, wearing mask, isolating and testing people will continue to remain important
Cadila Healthcare gains 6% on US FDA nod for mineral supplement
Zydus Cadila has received final approval from the US Food and Drug Administration to market Potassium Chloride extended-release tablets CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus Cadila receives final approval from USFDA for Potassium Chloride Extended-Release Tablets COVID-19 vaccine: 3 candidates under clinical trials, Serum Institute to begin Phase 3 study soon
COVID-19 vaccine candidates being developed by Cadila Healthcare and Bharat Biotech have completed the phase one of the study while Pune-based Serum Institute of India (SII) will begin with Phase 3 clinical trial after getting regulatory nod, says ICMR chief